Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Expression data from MDA-MB-231 cells treated with vehicle or YW3-56

OTHER RELATED OMICS DATASETS IN: E-GEOD-46590

PROVIDER: PRJNA201057 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data from MDA-MB-231 cells treated with vehicle or YW3-56

Project description:PAD4 is overexpressed in many cancer cells. We developed PAD inhibitors that efficiently inhibit the cancer cell growth. One inhibitor YW3-56 could efficiently induce cell death of triple negative breast cancer MDA-MB-231 cells. We used microarray to detail the global gene expression of MDA-MB-231 before and after YW3-56 treatment and identify significant up-regulated or down-regulated genes by YW3-56 MDA-MB-231 cells were cultured and treated with vehicle (DMSO) or YW3-56. Cells were washed with PBS and harvested for RNA extraction and hybridization on Affymetrix microarray.

2015-05-21 | E-GEOD-46590 | biostudies-arrayexpress

Proteomics of Triple Negative Breast Cancer Cells Treated with SU056

Project description:1. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and MCF12A cells were treated with DMSO (vehicle control) or SU056 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates. 2. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the resulting soluble and insoluble fractions were determined.3. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 YBOX1 KD cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the soluble fractions were determined.

2024-04-04 | PXD042380 | Pride

Non-allosteric Inhibition of Enolase 1 Impedes Growth of Triple-Negative Breast Cancer

Project description:1. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated for 6h with DMSO or SU212 and incubated at different temperatures and protein differences in the soluble fractions were determined. 2. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and BT549 cells were treated with DMSO (vehicle control) or SU212 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates.

2025-10-10 | PXD061466 | Pride

Homo sapiens

Project description:Expression data from MDA-MB-231 cells treated with dinaciclib

| PRJNA348737 | ENA

Homo sapiens

Project description:Expression data from parental MDA-MB-231 cells and MDA-MB-231(SA) variant

| PRJNA124283 | ENA

Expression data from MDA-MB-231 cells treated with vehicle or YW3-56

Project description:PAD4 is overexpressed in many cancer cells. We developed PAD inhibitors that efficiently inhibit the cancer cell growth. One inhibitor YW3-56 could efficently induce cell death of triple negative breast cancer MDA-MB-231 cells. We used microarray to detail the global gene expression of MDA-MB-231 before and after YW3-56 treatment and identify significant up-regulated or down-regulated genes by YW3-56

2015-05-21 | GSE46590 | GEO

E-GEOD-46590

Project description:Expression data from MDA-MB-231 cells treated with vehicle or YW3-56

2025-01-24 | E-GEOD-46590 | ExpressionAtlas

Homo sapiens

Project description:The miRNA profiling in MDA-MB-231, MDA-MB-231/E1A and knockdown of Dicer in MDA-MB-231/E1A cells

| PRJNA308943 | ENA

Homo sapiens

Project description:Expression data from KDM3A knockdown MDA-MB-231 cells

| PRJNA327095 | ENA

Homo sapiens

Project description:Expression data from breast cancer cells MDA-MB-231